Drugs and Clinical Trials in Alzheimer's Disease: Accessibility and Evidence in China
Clinical Trials & Advanced Therapies
Alzheimer's disease is the area where families most often ask about "new drugs in China" — and where the gap between what is approved, what is available and what is appropriate is widest. Three separate questions need separate answers: is the drug approved in China, can it be prescribed to this patient, and is there a trial that fits.
Approved treatment versus trial treatment
Standard care in China follows the same broad classes used internationally: cholinesterase inhibitors, memantine, and more recently anti-amyloid monoclonal antibodies in selected centres. Availability of the newest agents is uneven — approval, hospital formulary listing and physician experience are three different gates, and a drug can be approved nationally yet unavailable at the hospital in front of you.
Who is considered for anti-amyloid therapy
- Confirmed biomarker status — amyloid demonstrated by PET or cerebrospinal fluid, not by clinical impression alone
- Mild cognitive impairment or mild dementia stage; advanced disease is generally not eligible
- MRI without findings that raise the risk of amyloid-related imaging abnormalities
- No anticoagulation or conditions that make monitoring unsafe
What a trial adds and what it costs
Trials in China cover anti-amyloid antibodies, anti-tau approaches, and symptomatic agents. Enrolment usually requires a study partner who can attend visits, and follow-up can run for a year or more with regular MRI and cognitive testing. Ask who pays for the biomarker tests and the MRI monitoring, because these are often the largest costs and are not always covered by the sponsor.
Questions worth asking first
- Has the patient's biomarker status been established, and with which test?
- Is the treatment available at a centre that has used it, or only in principle?
- What monitoring schedule is required, and can it be done locally after the first visits?
Next step: send the cognitive assessment, MRI report and any biomarker results, and we will tell you which of the three routes is realistically open for this patient.
